Nasdaq
$3.12▲ 3.83%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $77.3MShares out 24.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.14Pre-market26.10.14 13:15filedEFFECTOther#●●●#●●●
Lexaria Bioscience Corp.
The registration statement for Lexaria Bioscience Corp. was declared effective by the SEC on October 13, 2026. This filing confirms the official approval of the company's registration documents, completing the legal requirements for future securities offerings or capital raising activities.…more
$3.12+3.83%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 06:15424B3Offering
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has registered for the potential resale of up to 923,827 shares of common stock issuable upon the exercise of Series A, Series B, and PA Warrants. While the company will not receive proceeds from the resale, it stands to gain up to $11,760,182 if all warrants are exercised for cash. This registration facilitates the selling stockholders' ability to trade their shares, with the company bearing the registration costs.…more
$3.12+3.83%vs prev closeView filingShare - 10.2Pre-market26.10.02 10:17filedS-3Offering
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has filed a Form S-3 registration statement for the resale of up to 923,827 shares of common stock issuable upon the exercise of warrants issued in September 2026. The company expects to receive aggregate proceeds of $11,760,182 upon the cash exercise of these warrants.…more
$3.12+3.83%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.21 22:29#●●●#●●●
Lexaria Bioscience Progresses Oral Semaglutide Pilot Study
Lexaria Bioscience has completed enrollment and continues scheduled dosing for its pilot study comparing DehydraTECH-semaglutide formulations to Wegovy tablets. The company expects to conclude dosing in mid-November and will report results following laboratory analysis.…more
$3.12+3.83%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.15Pre-market26.10.15 22:15
●●●●●●●● ●●●●● ●●●●●●
Lexaria Bioscience reported results from its animal study evaluating DehydraTECH-based CBD and semaglutide formulations. While some formulations showed improved brain absorption, semaglutide concentrations in brain tissue fell below the limit of quantification.…more
$3.12+3.83%vs prev closeShareBenzinga - 9.17Pre-market26.09.17 22:11
●●●●●●●● ●●●●● ●●●●●●
Lexaria Bioscience raised $7.9 million in net proceeds through an Australian tax refund and an institutional financing round. The company stated that it does not plan any further financings throughout 2026.…more
$3.12+3.83%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report